DOCSLIB.ORG

Drug Pipeline Monthly Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Pipeline Monthly Update Drug Pipeline Monthly Update Critical updates in an ever changing environment December 2018 New drug information ● Temixys™ (lamivudine/tenofovir disoproxil fumarate): The Food and Drug Administration (FDA) approved Celltrion’s Temixys in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, dosed once daily. Temixys is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) in one tablet. Celltrion intends to sell Temixys at a discounted price compared to Gilead’s Truvada® (emtricitabine/tenofovir disoproxil fumarate).1 Celltrion plans to launch early 2019.1 ● Tolsura™ (itraconazole) capsules: Mayne Pharma received FDA approval for Tolsura for the treatment of systemic fungal infections in adult patients including certain forms of: → blastomycosis, → histoplasmosis, and → aspergillosis Mayne notes that this is a Super-BioAvailable (SUBA) formulation of itraconazole that has been shown in clinical studies to have increased bioavailability and reduced variability when compared to other itraconazole formulations.2 Tolsura will launch in January 2019.2 ● Montegrity™ (prucalopride): The FDA approved Shire’s Montegrity, a once daily, oral medication for the treatment of adults with chronic idiopathic constipation (CIC). Montegrity will compete for market share in the CIC space with Allergan’s Linzess® (linaclotide), Takeda’s Amitiza® (lubiprostone), and Synergy’s Trulance® (plecanatide). Montegrity is anticipated to launch in 2019. continued While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner. Drug Pipeline Monthly Update: December 2018 Page 2 Generic drug information ● Fortesta® (testosterone transdermal gel pump): Actavis Pharma launched the first true generic of Endo Pharmaceuticals’ Fortesta gel pump. Fortesta is indicated in males for testosterone replacement therapy. Fortesta gel pump generated < $10 million in U.S. annual sales in 2017. ● Harvoni® (edipasvir/sofosbuvir): Asegua Therapeutics/Gilead launched an authorized generic for Gilead Science’s Harvoni that is indicated for the treatment of: → chronic hepatitis C virus (HCV) in adults with genotype 1, 4, 5, or 6 infections without cirrhosis or with compensated cirrhosis; → adults with genotype 1 infection with decompensated cirrhosis, in combination with ribavirin; → adults with genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin; and → pediatric patients 12 years of age and older or weighing at least 35 kg with genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis. Harvoni generated $5,549 million in U.S. annual sales in 2017. ● Epclusa® (sofosbuvir/velpatasvir): Asegua Therapeutics/Gilead launched an authorized generic of Gilead Science’s Epclusa for adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infections: → without cirrhosis or with compensated cirrhosis; → with decompensated cirrhosis for use in combination with ribavirin. Epclusa is expected to be protected from additional generic competition until 2032. Epclusa generated $2,747 million in U.S. annual sales in 2017. ● Zytiga® (abiraterone): Teva Pharmaceuticals, Hikma, and Mylan launched their generic versions of Janssen Biotech’s Zytiga 250 mg tablet which is indicated in combination with prednisone for the treatment of patients with: → metastatic castration-resistant prostate cancer (CRPC); and → metastatic high-risk castration-sensitive prostate cancer (CSPC). Teva, Hikma, and Mylan have shared 180-day exclusivity. Patriot launched an authorized generic version of Zytiga 250 mg. Zytiga 500 mg tablets are not available generically. Zytiga generated $1,224 million in U.S. in 2017. ● Epipen® (epinephrine auto-injector): Teva Pharmaceuticals launched the first true generic version of Mylan Specialty’s Epipen 0.3 mg auto-injector indicated for the emergency treatment of allergic reactions (Type I) including anaphylaxis. Epipen had annual U.S. sales of $763 million in 2017. ● Rapaflo® (silodosin): Sandoz launched the first generic version of Allergan’s Rapaflo capsule for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Multiple manufacturers have since launched their generic versions of Rapaflo. Rapaflo brand generated $206 million in U.S. sales in 2017. ● Amicar® (aminocaproic acid): Vitruvias Therapeutics launched the first true generic of Clover Pharmaceuticals’ Amicar tablet 1000 mg indicated to enhance hemostasis when fibrinolysis contributes to bleeding. Amicar generated $53 million in annual U.S. sales in 2017. Drug Pipeline Monthly Update: December 2018 Page 3 New molecular entity approvals in the past twelve months Generic name Brand name Manufacturer Indication(s) Date approved* prucalopride Montegrity™ Shire CIC December 2018 rifamycin Aemcolo™ Cosmo Travelers’ diarrhea November 2018 Pharmaceuticals revefenacin Yupelri™ AcelRx COPD November 2018 Pharmaceuticals baloxavir marboxil Xofluza™ Shinogi & Co Influenza October 2018 omadacycline Nuzyra™ Paratek Pneumonia and skin infections October 2018 Pharmaceuticals sarecycline Seysara™ Allergan and Paratek Acne October 2018 Pharmaceuticals galcanezumab-gnlm Emgality™ Eli Lilly Prevention of migraine September 2018 fremanezumab-vfrm Ajovy™ Teva Prevention of migraine September 2018 doravirine Pifeltro™ Merck HIV September 2018 eravacycline Xerava™ Tetraphase Pharma Complicated intra-abdominal infections September 2018 segesterone acetate/ Annovera™ TherapeuticsMD Inc Pregnancy prevention August 2018 ethinyl estradiol elagolix Orilissa® AbbVie Pain with endometriosis July 2018 tafenoquine Krintafel® GSK Radical cure of P. vivax malaria July 2018 tecovirimat Tpoxx™ Siga Technologies Smallpox July 2018 glycopyrronium tosylate Qbrexa™ Dermina Excessive sweating July 2018 plazomicin Zemdri™ Achaogen Complicated urinary tract infections July 2018 moxidectin Moxidectin™ Medicines River blindness June 2018 Development for Global Health erenumab-aooe Aimovig® Amgen/Novartis Prevention of migraine May 2018 sodium zirconium cyclosilicate Lokelma™ AstraZeneca Hyperkalemia May 2018 lofexidine Lucemyra™ US WorldMeds Mitigation of opioid withdrawal symptoms May 2018 coagulation factor Xa Andexxa® Portola Factor Xa reversal agent May 2018 (recombinant), inactivated-zhza bictegravir/emtricitabine/ Biktarvy™ Gilead HIV February 2018 tenofovir alafenamide *Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product’s manufacturer. continued Drug Pipeline Monthly Update: December 2018 Page 4 Other new product approvals in the past twelve months Generic name Brand name Manufacturer Indication(s) Date approved* itraconazole capsule Tolsura™ Mayne Pharma Fungal infections December 2018 lamivudine/tenofovir disoproxil Temixys™ Celltrion HIV November 2018 fumarate sufentanil Dsuvia™ AcelRx Pain November 2018 Pharmaceuticals clobazam oral soluble film (OSF) Sympazan™ Aquestive Lennox-Gastaut syndrome November 2018 Therapeutics levoleucovorin Khapzory™ Spectrum Rescue after high-dose methotrexate October 2018 therapy halobetasol propionate lotion Bryhali™ Bausch Health Cos Plaque psoriasis October 2018 0.01% Inc (Valeant) meloxicam orally disintegrating Qmiiz ODT™ TerSera Pain and inflammation October 2018 tables estradiol and progesterone Bijuva™ TherapeuticsMD Vasomotor symptoms due to menopause October 2018 testosterone enanthate Xyosted™ Antares Testosterone replacement therapy October 2018 latanoprost Xelpros™ Sun Pharma Open-angle glaucoma September 2018 buprenorphine/naloxone SL film Cassipa™ Teva Opioid dependence September 2018 doravirine, lamivudine and Delstrigo™ Merck HIV September 2018 tenofovir disoproxil fumarate loteprednol etabonate Inveltys™ Kala Pharmaceuticals Post-operative inflammation and pain September 2018 following ocular surgery tretinoin Altreno™ Ortho Dermatologic Acne September 2018 methylphenidate Jornay PM™ Ironshore ADHD August 2018 Pharmaceuticals cyclosporine Cequa™ Sun Pharma Dry eye disease August 2018 tafenoquine Arakoda™ 60 Degrees Prevention of malaria August 2018 Pharmaceuticals risperidone injectable Perseris™ Indivior Schizophrenia August 2018 pimavanserin, 34 mg capsule, Nuplaxid® Acadia Parkinson’s disease psychosis July 2018 10 mg tablet Pharmaceutical darunavir, cobicistat, Symtuza® Janssen HIV July 2018 emtricitabine, tenofovir alafenamide aripiprazole lauroxil Aristada Initio™ Alkermes Schizophrenia July 2018 desmopressin Nocdurna™ Ferring Nocturia July 2018 Pharmaceuticals celecoxib/amlodipine Consensi™ Kitov Pharma Osteoarthritis pain/hypertension May 2018 vaginal estradiol Imvexxy™ TherapeuticsMD Menopause symptoms May 2018 polyethylene glycol 3350, sodium Plenvu® Norgine Osmotic laxative May 2018 ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution continued Drug Pipeline Monthly Update: December 2018 Page 5 Other new product approvals in the past 12 months (continued) Generic name Brand name Manufacturer Indication(s) Date approved* efavirenz, lamivudine, tenofovir Symfi™ Mylan HIV April 2018 disoproxil fumarate efavirenz, lamivudine,
Load more

Recommended publications
  • Gastrointestinal (GI) Motility, Chronic Therapeutic Class Review
    Gastrointestinal (GI) Motility, Chronic Therapeutic Class Review (TCR) March 7, 2019 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. March 2019 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004–2019 Magellan Rx Management. All Rights Reserved. FDA-APPROVED INDICATIONS Drug Manufacturer Indication(s) alosetron (Lotronex®)1 generic, .
    [Show full text]
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • Inclusion and Exclusion Criteria for Each Key Question
    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE in PETS Introduction Pathophysiology/Etiology to That Observed in Dogs
    VETTALK Volume 15, Number 04 American College of Veterinary Pharmacists THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE IN PETS Introduction Pathophysiology/Etiology to that observed in dogs. It can be The moving topic of this Vet Talk As with most diseases in the veteri- due to a trichobezoar, dehydration, newsletter will be prokinetic medica- nary world, the etiology and patho- obesity, old age, diabetes, immobility, tions. The availability of information physiology of constipation are varied pain from trauma to the low back, on the many prokinetic agents is var- depending on the species being dis- bladder infection, or an anal sac infec- ied at best so an overall consensus of cussed, where in their gastrointestinal tion. In cases that are more chronic, prokinetic medications will be as- tract the problem is occurring, and underlying disease such as colitis or sessed in this article, hopefully giving any accompanying comorbid condi- Irritable Bowel Syndrome (IBS) may better insight to practitioners about tions. be the culprit. On the other hand, the which agents to use in their patients. cause may be idiopathic which is Canines: In man’s best friend, consti- frustrating for both veterinarian and Prevalence pation has many origins. A dog’s patient since this form is most diffi- Chronic constipation and gastroin- digestive tract itself is complex but cult to treat. testinal stasis are highly debilitating ultimately the mass movements and conditions that not only affect human haustral contractions from the large Equines: Despite their large size, patients but our four legged patients intestine (colon), propel feces into the horses have incredibly delicate diges- as well! Though this condition is rectum stimulating the internal anal tive systems.
    [Show full text]
  • Keeping up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth A
    Keeping Up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth A. Shlom, PharmD, BCPS Senior Vice President & Director Clinical Pharmacy Program | Acurity, Inc. Privileged and Confidential April 10, 2019 Privileged and Confidential Program Objectives By the end of the presentation, the pharmacist or pharmacy technician participant will be able to: ▪ Identify orphan drugs and first-in-class medications approved by the FDA in 2018. ▪ List five new drugs and their indications. ▪ Identify the place in therapy for three novel monoclonal antibodies. ▪ Discuss at least two new medications that address public health concerns. Dr. Shlom does not have any conflicts of interest in regard to this presentation. Both trade names and generic names will be discussed throughout the presentation Privileged and Confidential 2018 NDA Approvals (NMEs/BLAs) ▪ Lutathera (lutetium Lu 177 dotatate) ▪ Braftovi (encorafenib) ▪ Vizimpro (dacomitinib) ▪ Biktarvy (bictegravir, emtricitabine, ▪ TPOXX (tecovirimat) ▪ Libtayo (cemiplimab-rwic) tenofovir, ▪ Tibsovo (ivosidenib) ▪ Seysara (sarecycline) alafenamide) ▪ Krintafel (tafenoquine) ▪ Nuzyra (omadacycline) ▪ Symdeko (tezacaftor, ivacaftor) ▪ Orilissa (elagolix sodium) ▪ Revcovi (elapegademase-lvir) ▪ Erleada (apalutamide) ▪ Omegaven (fish oil triglycerides) ▪ Tegsedi (inotersen) ▪ Trogarzo (ibalizumab-uiyk) ▪ Mulpleta (lusutrombopag) ▪ Talzenna (talazoparib) ▪ Ilumya (tildrakizumab-asmn) ▪ Poteligeo (mogamulizumab-kpkc) ▪ Xofluza (baloxavir marboxil) ▪ Tavalisse (fostamatinib disodium) ▪ Onpattro (patisiran)
    [Show full text]
  • The Pharmacology of Prokinetic Agents and Their Role in the Treatment of Gastrointestinal Disorders
    The Pharmacology of ProkineticAgents IJGE Issue 4 Vol 1 2003 Review Article The Pharmacology of Prokinetic Agents and Their Role in the Treatment of Gastrointestinal Disorders George Y. Wu, M.D, Ph.D. INTRODUCTION Metoclopramide Normal peristalsis of the gut requires complex, coordinated neural and motor activity. Pharmacologic Category : Gastrointestinal Abnormalities can occur at a number of different Agent. Prokinetic levels, and can be caused by numerous etiologies. This review summarizes current as well as new Symptomatic treatment of diabetic gastric agents that show promise in the treatment of stasis gastrointestinal motility disorders. For these Gastroesophageal reflux e conditions, the most common medications used in s Facilitation of intubation of the small the US are erythromycin, metoclopramide, and U intestine neostigmine (in acute intestinal pseudo- Prevention and/or treatment of nausea and obstruction). A new prokinetic agent, tegaserod, vomiting associated with chemotherapy, has been recently approved, while other serotonin radiation therapy, or post-surgery (1) agonist agents (prucalopride, YM-31636, SK-951, n ML 10302) are currently undergoing clinical o Blocks dopamine receptors in chemoreceptor i t studies. Other prokinetics, such as domperidone, c trigger zone of the CNS (2) A are not yet approved in the US, although are used in f Enhances the response to acetylcholine of o other countries. tissue in the upper GI tract, causing enhanced m s i n motility and accelerated gastric emptying a DELAYED GASTRIC EMPTYING OR h without stimulating gastric, biliary, or c G A S T R O E S O P H A G E A L R E F L U X e pancreatic secretions.
    [Show full text]
  • The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak
    viruses Perspective The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak Scott A. Foster 1,*, Scott Parker 2 ID and Randall Lanier 1 1 Chimerix, Durham, NC 27713, USA; [email protected] 2 Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-597-7741 Received: 29 September 2017; Accepted: 26 October 2017; Published: 30 October 2017 Abstract: Smallpox (variola) virus is considered a Category A bioterrorism agent due to its ability to spread rapidly and the high morbidity and mortality rates associated with infection. Current recommendations recognize the importance of oral antivirals and call for having at least two smallpox antivirals with different mechanisms of action available in the event of a smallpox outbreak. Multiple antivirals are recommended due in large part to the propensity of viruses to become resistant to antiviral therapy, especially monotherapy. Advances in synthetic biology heighten concerns that a bioterror attack with variola would utilize engineered resistance to antivirals and potentially vaccines. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo, has a different mechanism of action from tecovirimat (the only oral smallpox antiviral currently in the US Strategic National Stockpile), and has a resistance profile that reduces concerns in the scenario of a bioterror attack using genetically engineered smallpox. Given the devastating potential of smallpox as a bioweapon, preparation of a multi-pronged defense that accounts for the most obvious bioengineering possibilities is strategically imperative. Keywords: smallpox; variola virus; bioterrorism; bioweapon; brincidofovir; CMX001; antiviral 1.
    [Show full text]
  • Marketing Authorisations Granted in December 2020
    Marketing authorisations granted in December 2020 PL Number Grant Date MA Holder Licensed Name(s) Active Ingredient Quantity Units Legal Status Territory PL 14251/0100 01/12/2020 MANX HEALTHCARE LIMITED COLCHICINE 500 MICROGRAMS TABLETS COLCHICINE 0.500 MILLIGRAMS POM UK PL 34424/0050 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 25MG FILM-COATED TABLETS SPIRONOLACTONE 25 MILLIGRAMS POM UK PL 34424/0051 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 50MG FILM-COATED TABLETS SPIRONOLACTONE 50 MILLIGRAMS POM UK PL 34424/0052 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 100MG FILM-COATED TABLETS SPIRONOLACTONE 100 MILLIGRAMS POM UK PL 36282/0021 03/12/2020 RIA GENERICS LIMITED COLCHICINE 500 MICROGRAM TABLETS COLCHICINE 500 MICROGRAMS POM UK PL 39352/0439 03/12/2020 KOSEI PHARMA UK LIMITED FROVATRIPTAN 2.5 MG FILM-COATED TABLETS FROVATRIPTAN SUCCINATE MONOHYDRATE 2.5 MILLIGRAMS POM UK PL 31750/0174 04/12/2020 SUN PHARMACEUTICAL INDUSTRIES EUROPE BV CETRORELIX SUN 0.25 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE CETRORELIX ACETATE 0.25 MILLIGRAMS PER MILLILITRE POM UK PL 34424/0054 04/12/2020 KEY PHARMACEUTICALS LIMITED ALIMEMAZINE TARTRATE 10MG FILM COATED TABLETS ALIMEMAZINE TARTRATE 10.00 MILLIGRAMS POM UK PL 17780/0858 07/12/2020 ZENTIVA PHARMA UK LIMITED FINGOLIMOD ZENTIVA 0.5 MG HARD CAPSULES FINGOLIMOD HYDROCHLORIDE 0.56 MILLIGRAMS POM UK PL 01502/0113 08/12/2020 HAMELN PHARMA LTD AMIODARONE HYDROCHLORIDE 20 MG/ML SOLUTION FOR INFUSION AMIODARONE HYDROCHLORIDE 20 MILLIGRAMS POM UK PL 16786/0006 08/12/2020
    [Show full text]
  • Prucalopride (SHP555) Update for Global Investors
    Prucalopride (SHP555) Update for Global Investors March 7, 2018 STATEMENTS REGARDING PRUCALOPRIDE SUBJECT TO REGULATORY APPROVAL - INTENDED FOR INVESTOR AUDIENCE ONLY Prucalopride - Introduction U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation (CIC) • Prucalopride is an investigational product for the treatment of chronic idiopathic constipation in adults in the U.S. • The product is investigational. The U.S. FDA accepted submission of Shire’s NDA and the PDUFA date is on or around December 21, 2018 • Shire does not know when or if FDA will approve prucalopride • Shire cannot predict the content of the labeling for prucalopride in the event of FDA approval • This presentation updates investors on Shire’s current development plan for prucalopride 2 STATEMENTS REGARDING PRUCALOPRIDE SUBJECT TO REGULATORY APPROVAL - INTENDED FOR INVESTOR AUDIENCE ONLY Prucalopride - Summary U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation (CIC) • Reinforces Shire’s long-standing heritage in gastrointestinal (GI) conditions and deep customer relationships and in-house capabilities • Strong addition to GI franchise, which includes LIALDA, GATTEX and provides bridge to pipeline assets such as SHP621 and SHP647 • If approved, prucalopride will be the only readily available 5-HT4 agonist1 in the U.S. to treat CIC in adults • CIC affects an estimated 35 million people in the U.S.2,3* Many patients are dissatisfied with or do not respond to current therapies4 • Efficacy and safety evaluated in five main Phase 3 and one Phase 4 double-blind, placebo-controlled clinical trials5,6 • NDA submission includes real-world evidence from an observational, pharmacoepidemiology cardiovascular safety study7 *This represents ~14% of the U.S.
    [Show full text]
  • Gastroparesis: 2014
    GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #1 Richard W. McCallum, MD, FACP, FRACP (Aust), FACG Status of Pharmacologic Management of Gastroparesis: 2014 Richard W. McCallum Joseph Sunny, Jr. Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction of the gastric outlet or small intestine. The main etiologies are diabetes, idiopathic and post- gastric and esophageal surgical settings. The management of gastroparesis is challenging due to a limited number of medications and patients often have symptoms, which are refractory to available medications. This article reviews current treatment options for gastroparesis including adverse events and limitations as well as future directions in pharmacologic research. INTRODUCTION astroparesis is a syndrome characterized by documented gastroparesis are increasing.2 Physicians delayed emptying of gastric contents without have both medical and surgical approaches for these Gmechanical obstruction of the stomach, pylorus or patients (See Figure 1). Medical therapy includes both small bowel. Patients can present with nausea, vomiting, prokinetics and antiemetics (See Table 1 and Table 2). postprandial fullness, early satiety, pressure, fullness The gastroparesis population will grow as diabetes and abdominal distension. In addition, abdominal pain increases and new therapies will be required. What located in the epigastrium, and distinguished from the do we know about the size of the gastroparetic term discomfort, is increasingly being recognized population? According to a study from the Mayo Clinic as an important symptom. The main etiologies of group surveying Olmsted County in Minnesota, the gastroparesis are diabetes, idiopathic, and post gastric risk of gastroparesis in Type 1 diabetes mellitus was and esophageal surgeries.1 Hospitalizations from significantly greater than for Type 2.
    [Show full text]
  • Zelnorm Page: 1 of 5
    Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.25 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Gastrointestinal Agents Original Policy Date: April 26, 2019 Subject: Zelnorm Page: 1 of 5 Last Review Date: March 13, 2020 Zelnorm Description Zelnorm (tegaserod) Background Zelnorm is an agonist of serotonin type-4 (5-HT4) receptors that stimulates the peristaltic reflex and intestinal secretion, inhibits visceral sensitivity, enhances basal motor activity, and normalizes impaired motility throughout the gastrointestinal tract (1). Regulatory Status FDA-approved indication: Zelnorm is a serotonin-4 (5-HT4) receptor agonist indicated for treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C) (1). Limitations of Use: The safety and effectiveness of Zelnorm in men with IBS-C have not been established (1). Zelnorm is contraindicated in patients with: (1) 1. A history of myocardial infarction (MI), stroke, transient ischemic attack (TIA), or angina. 2. A history of ischemic colitis or other forms of intestinal ischemia. 3. Severe renal impairment (eGFR < 15 mL/min/1.73 m2) or end-stage renal disease. 4. Moderate and severe hepatic impairment (Child-Pugh B or C). 5. A history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi Dysfunction, or abdominal adhesions. 5.50.25 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Gastrointestinal Agents Original Policy Date: April 26, 2019 Subject: Zelnorm Page: 2 of 5 The safety and effectiveness of Zelnorm in pediatric patients less than 18 years of age have not been established (1).
    [Show full text]